image
Healthcare - Drug Manufacturers - Specialty & Generic - NASDAQ - US
$ 121.61
8.36 %
$ 12 B
Market Cap
36.15
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on May, 8, 2025.

The intrinsic value of one NBIX stock under the worst case scenario is HIDDEN Compared to the current market price of 122 USD, Neurocrine Biosciences, Inc. is HIDDEN

This DCF valuation model was last updated on May, 8, 2025.

The intrinsic value of one NBIX stock under the base case scenario is HIDDEN Compared to the current market price of 122 USD, Neurocrine Biosciences, Inc. is HIDDEN

This DCF valuation model was last updated on May, 8, 2025.

The intrinsic value of one NBIX stock under the best case scenario is HIDDEN Compared to the current market price of 122 USD, Neurocrine Biosciences, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart NBIX

image
$160.0$160.0$150.0$150.0$140.0$140.0$130.0$130.0$120.0$120.0$110.0$110.0$100.0$100.0$90.0$90.0$80.0$80.015 Nov15 NovDec '24Dec '2415 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 AprMay '25May '25
FINANCIALS
2.36 B REVENUE
24.81%
570 M OPERATING INCOME
127.38%
341 M NET INCOME
36.68%
595 M OPERATING CASH FLOW
52.71%
-127 M INVESTING CASH FLOW
72.85%
-487 M FINANCING CASH FLOW
-745.33%
573 M REVENUE
-8.78%
23.6 M OPERATING INCOME
-83.38%
7.9 M NET INCOME
-92.34%
64.8 M OPERATING CASH FLOW
-73.28%
14.2 M INVESTING CASH FLOW
120.79%
-118 M FINANCING CASH FLOW
59.34%
Balance Sheet Neurocrine Biosciences, Inc.
image
Current Assets 1.72 B
Cash & Short-Term Investments 1.08 B
Receivables 479 M
Other Current Assets 170 M
Non-Current Assets 1.99 B
Long-Term Investments 864 M
PP&E 592 M
Other Non-Current Assets 538 M
28.94 %12.88 %4.56 %23.24 %15.92 %14.46 %Total Assets$3.7b
Current Liabilities 508 M
Accounts Payable 110 M
Short-Term Debt 0
Other Current Liabilities 398 M
Non-Current Liabilities 621 M
Long-Term Debt 0
Other Non-Current Liabilities 621 M
9.74 %35.23 %55.03 %Total Liabilities$1.1b
EFFICIENCY
Earnings Waterfall Neurocrine Biosciences, Inc.
image
Revenue 2.36 B
Cost Of Revenue 34 M
Gross Profit 2.32 B
Operating Expenses 1.75 B
Operating Income 570 M
Other Expenses 229 M
Net Income 341 M
3b3b2b2b2b2b1b1b500m500m002b(34m)2b(2b)571m(229m)341mRevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
98.56% GROSS MARGIN
98.56%
24.22% OPERATING MARGIN
24.22%
14.49% NET MARGIN
14.49%
13.18% ROE
13.18%
9.18% ROA
9.18%
12.48% ROIC
12.48%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Neurocrine Biosciences, Inc.
image
600m600m500m500m400m400m300m300m200m200m100m100m00(100m)(100m)(200m)(200m)20162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income 341 M
Depreciation & Amortization 27.1 M
Capital Expenditures -38.2 M
Stock-Based Compensation 196 M
Change in Working Capital 0
Others 155 M
Free Cash Flow 557 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Neurocrine Biosciences, Inc.
image
Wall Street analysts predict an average 1-year price target for NBIX of $157 , with forecasts ranging from a low of $121 to a high of $193 .
NBIX Lowest Price Target Wall Street Target
121 USD -0.50%
NBIX Average Price Target Wall Street Target
157 USD 28.81%
NBIX Highest Price Target Wall Street Target
193 USD 58.70%
Price
Max Price Target
Min Price Target
Average Price Target
2002001801801601601401401201201001008080Jun '24Jun '24Jul '24Jul '24Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 12
6. Ownership
Insider Ownership Neurocrine Biosciences, Inc.
image
Sold
0-3 MONTHS
3.31 M USD 1
3-6 MONTHS
39.1 M USD 11
6-9 MONTHS
2.66 M USD 2
9-12 MONTHS
22.5 M USD 9
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Neurocrine Biosciences to Present at Upcoming Investor Conferences in May SAN DIEGO , May 6, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will participate at two upcoming investor conferences in May. Chief Executive Officer Kyle Gano and Vice-President of Investor Relations Todd Tushla will present at the BofA Securities 2025 Health Care Conference on Tuesday, May 13, 2025 at 11:20 AM Pacific Time in Las Vegas. prnewswire.com - 2 weeks ago
Neurocrine Biosciences' Ingrezza Q1 Sales Prove Resilient, Analysts Boost Price Target Neurocrine Biosciences Inc. NBIX stock is trading higher on Tuesday after the company reported better-than-expected first-quarter 2025 earnings. benzinga.com - 2 weeks ago
Neurocrine Biosciences Surges On 'Surprising' Momentum For Its Newest Drug Neurocrine Biosciences shares catapulted Tuesday on "surprising commercial momentum" for its newest drug, Crenessity. investors.com - 2 weeks ago
2 Pharma Stocks Staging Big Post-Earnings Moves Biopharmaceutical giants Vertex Pharmaceuticals Inc  (NASDAQ:VRTX) and Neurocrine Biosciences Inc (NASDAQ:NBIX) are fresh out of the earnings confessional, with very different results. schaeffersresearch.com - 2 weeks ago
Neurocrine Biosciences and Carnie Wilson Team Up to Launch ConnectING with Carnie™ Awareness Campaign for People with Tardive Dyskinesia New multimedia awareness campaign empowers people living with tardive dyskinesia to stand up to stigma and speak openly with their healthcare provider about symptoms and treatment SAN DIEGO , May 6, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the launch of ConnectING with Carnie™, a multimedia awareness campaign in partnership with Grammy-nominated singer-songwriter and mental health advocate, Carnie Wilson. The campaign aims to support people struggling with the uncontrolled movements of tardive dyskinesia, an involuntary movement disorder associated with the use of antipsychotic medications, by sharing stories of courage and resilience in seeking diagnosis and treatment. prnewswire.com - 2 weeks ago
Neurocrine Biosciences, Inc. (NBIX) Q1 2025 Earnings Call Transcript Neurocrine Biosciences, Inc. (NASDAQ:NBIX ) Q1 2025 Results Conference Call May 5, 2025 4:30 PM ET Company Participants Todd Tushla - Vice President of Investor Relations Kyle Gano - Chief Executive Officer Matt Abernethy - Chief Financial Officer Eric Benevich - Chief Commercial Officer Dr. Eiry Roberts - Chief Medical Officer Conference Call Participants Paul Matteis - Stifel Tazeen Ahmad - Bank of America Phil Nadeau - TD Cowen Brian Abrahams - RBC Capital Markets David Amsellem - Piper Sandler Anupam Rama - JPMorgan Josh Schimmer - Cantor Jay Olson - Oppenheimer Cory Kasimov - Evercore Brian Skorney - Baird Marc Goodman - Leerink Partners Mike Riad - Morgan Stanley Ash Verma - UBS Myles Minter - William Blair Laura Chico - Wedbush Operator Good day, everyone, and welcome to Neurocrine Biosciences Reports First Quarter 2025 Results. At this time, all participants are in a listen only mode. seekingalpha.com - 2 weeks ago
Neurocrine (NBIX) Reports Q1 Earnings: What Key Metrics Have to Say Although the revenue and EPS for Neurocrine (NBIX) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers. zacks.com - 2 weeks ago
Neurocrine Biosciences (NBIX) Q1 Earnings Miss Estimates Neurocrine Biosciences (NBIX) came out with quarterly earnings of $0.08 per share, missing the Zacks Consensus Estimate of $0.43 per share. This compares to earnings of $0.42 per share a year ago. zacks.com - 2 weeks ago
Neurocrine Biosciences Reports First Quarter 2025 Financial Results and Reaffirms 2025 Financial Guidance INGREZZA® (valbenazine) First-Quarter 2025 Net Product Sales of $545 Million and Reaffirms 2025 Net Product Sales Guidance of $2.5 - $2.6 Billion CRENESSITYTM (crinecerfont) First-Quarter 2025 Net Product Sales of $14.5 Million with 413 Total Patient Enrollment Start Forms Initiated Phase 3 Registrational Programs for Osavampator in Major Depressive Disorder and NBI-'568 in Schizophrenia to Position for Next Phase of Growth SAN DIEGO , May 5, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its financial results for the first quarter ended March 31, 2025, and reaffirms its 2025 financial guidance. "We delivered a record number of new patient starts for INGREZZA, which is especially impressive given the typically challenging first quarter. prnewswire.com - 2 weeks ago
Neurocrine Biosciences Announces New Survey Revealing Need for Routine Screening and Earlier Diagnosis for People Living with Tardive Dyskinesia -- Majority of individuals polled reported tardive dyskinesia negatively impacts their day-to-day ability to function, including individuals living with mild or moderate uncontrolled movements1 SAN DIEGO , May 5, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the release of findings from a new survey conducted by The Harris Poll highlighting the profound negative impact of tardive dyskinesia on patients and reinforcing the need for routine screening, earlier diagnosis and treatment. The findings revealed that 80% of people living with tardive dyskinesia surveyed wished they had been screened for the condition earlier, and 86% wished their provider had discussed available treatment options for their uncontrolled movements sooner.1*   The survey results come during Tardive Dyskinesia (TD) Awareness Week, May 4-10. prnewswire.com - 2 weeks ago
Nxera Pharma's Partner Neurocrine Biosciences Initiates Phase 3 Registrational Program of NBI-1117568 as a Potential Treatment for Adults with Schizophrenia Tokyo, Japan and Cambridge, UK, 1 May 2025 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) today announces that its partner Neurocrine Biosciences Inc. (“Neurocrine”) has initiated a Phase 3 registrational program to evaluate the efficacy, safety and tolerability of NBI-1117568 (NBI-'568), an investigational oral muscarinic M4 selective orthosteric agonist, as a potential treatment for schizophrenia. Positive top-line data for the Phase 2 clinical study in adults with schizophrenia were reported in August 2024. globenewswire.com - 2 weeks ago
Neurocrine Biosciences Initiates Phase 3 Registrational Program for NBI-1117568 as Potential Treatment for Adults with Schizophrenia SAN DIEGO , April 30, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the initiation of a Phase 3 registrational program to evaluate the efficacy, safety and tolerability of NBI-1117568, the company's investigational oral muscarinic M4 selective orthosteric agonist, as a potential treatment for schizophrenia. Positive top-line data for the Phase 2 clinical study in adults with schizophrenia were reported in August 2024. prnewswire.com - 2 weeks ago
8. Profile Summary

Neurocrine Biosciences, Inc. NBIX

image
COUNTRY US
INDUSTRY Drug Manufacturers - Specialty & Generic
MARKET CAP $ 12 B
Dividend Yield 0.00%
Description Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, a VMAT2 inhibitor for the treatment of tardive dyskinesia. The company's commercial products include ONGENTYS, a catechol-O-methyltransferase inhibitor used as an adjunct therapy to levodopa/DOPA decarboxylase inhibitors for patients with Parkinson's disease; ORILISSA for the management of moderate to severe endometriosis pain in women; and ORIAHNN, a non-surgical oral medication option for the management of heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women. Its product candidates in clinical development include NBI-921352 for treating pediatric patients, as well as adult focal epilepsy indications; and NBI-827104 to treat rare pediatric epilepsy and essential tremor. The company's products in clinical development also comprise NBI-1065845 for the treatment of major depressive disorder; NBI-1065846 for treating anhedonia in major depressive disorder; and NBI-118568 for the treatment of schizophrenia. It has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. Neurocrine Biosciences, Inc. was incorporated in 1992 and is headquartered in San Diego, California.
Contact 12780 El Camino Real, San Diego, CA, 92130 https://www.neurocrine.com
IPO Date May 23, 1996
Employees 1800
Officers Dr. Lawrence Steinman BA, M.D., Ph.D. Co-Founder of Neurocrine Jane Sorensen Head of Investor Relations Dr. Jude Onyia Ph.D. Chief Scientific Officer Mr. Kyle W. Gano Ph.D. Chief Executive Officer & Director Mr. Eric S. Benevich Chief Commercial Officer Dr. Wylie W. Vale Ph.D. Co-Founder Mr. Matthew C. Abernethy CPA Chief Financial Officer Dr. Eiry Wyn Roberts M.D. Chief Medical Officer Mr. Darin M. Lippoldt Esq. Chief Legal Officer & Corporate Secretary Ms. Julie S. Cooke Chief Human Resources Officer